Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-week, Placebo- Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computed Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma

Trial Profile

Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-week, Placebo- Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computed Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Reslizumab (Primary) ; Fludeoxyglucose F-18
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms DEAR
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 31 Mar 2019 to 11 May 2019.
    • 02 Nov 2017 Planned primary completion date changed from 28 Feb 2019 to 11 Apr 2019.
    • 23 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top